Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline Review, H1 2012

Global Markets Direct
April 19, 2012
119 Pages - SKU: GMD3866357
Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2012', provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) therapeutic pipeline. This report provides information on the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury). 'Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Acute Renal Failure (ARF) (Acute Kidney Injury).
  • A review of the Acute Renal Failure (ARF) (Acute Kidney Injury) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline on the basis of route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline depth and focus of Acute Renal Failure (ARF) (Acute Kidney Injury) therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.



More Renal reports by Global Markets Direct

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H1 2014 by Global Markets Direct
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H1 2014SummaryGlobal Markets Direct’s, ‘End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline ...
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2014 by Global Markets Direct
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2014SummaryGlobal Markets Direct’s, ‘Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 ...
Renal Cell Carcinoma - Pipeline Review, H1 2014 by Global Markets Direct
Renal Cell Carcinoma - Pipeline Review, H1 2014SummaryGlobal Markets Direct’s, ‘Renal Cell Carcinoma - Pipeline Review, H1 2014’, provides an overview of the Renal Cell ...
Polycystic Kidney Disease - Pipeline Review, H1 2014 by Global Markets Direct
Polycystic Kidney Disease - Pipeline Review, H1 2014SummaryGlobal Markets Direct’s, ‘Polycystic Kidney Disease - Pipeline Review, H1 2014’, provides an overview of the Polycystic Kidney ...
See all reports like this >>

 

SELECT A LICENSE

    Online Download  USD 500  
    Site License  USD 1,000  
    Global Site License  USD 1,500  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!